Impax Laboratories

Partnership aims to make insulin more affordableCVS, Novo Nordisk launch a prescription savings program to help patients afford essential medications.
A host of new generics launch in 2015A look at some of the year's launches from key manufacturers.
FDA approves Rytary for Parkinson’s diseaseFDA approved an extended-release oral capsule formulation of carbidopa-levodopa (Rytary, Impax Pharmaceuticals, a division of Impax Laboratories, Inc.) for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.